메뉴 건너뛰기




Volumn 54, Issue 2, 2010, Pages 244-249

Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates;Resposta dos marcadores de curto prazo a teriparatida e ranelato de estrôncio em pacientes com osteoporose previamente tratados com bisfosfonatos

Author keywords

Bone remodeling; Osteocalcin; Osteoporosis; Strontium ranelate; Teriparatide; CTX

Indexed keywords


EID: 77952728933     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302010000200023     Document Type: Article
Times cited : (13)

References (29)
  • 1
    • 22344456666 scopus 로고    scopus 로고
    • Pharmacological management of severe postmenopausal osteoporosis
    • Gandio A, Morabito N. Pharmacological management of severe postmenopausal osteoporosis. Drugs Aging. 2005;22(5):405-17.
    • (2005) Drugs Aging , vol.22 , Issue.5 , pp. 405-417
    • Gandio, A.1    Morabito, N.2
  • 2
    • 33947537963 scopus 로고    scopus 로고
    • Update in osteoporosis and metabolic bone disorders
    • Shoback D. Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab. 2007;92:747-53.
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 747-753
    • Shoback, D.1
  • 3
    • 34548306408 scopus 로고    scopus 로고
    • Mechanisms of anabolic therapies for osteoporosis
    • Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905-16.
    • (2007) N Engl J Med , vol.357 , Issue.9 , pp. 905-916
    • Canalis, E.1    Giustina, A.2    Bilezikian, J.P.3
  • 4
    • 37349017937 scopus 로고    scopus 로고
    • Bone quality: The material and structural basis of bone strength
    • Seeman E. Bone quality: the material and structural basis of bone strength. J Bone Miner Metab. 2008;26(1):1-8.
    • (2008) J Bone Miner Metab , vol.26 , Issue.1 , pp. 1-8
    • Seeman, E.1
  • 5
    • 0141684971 scopus 로고    scopus 로고
    • The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
    • Black D, Greenspan S, Ensrud K, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207-15.
    • (2003) N Engl J Med , vol.349 , pp. 1207-1215
    • Black, D.1    Greenspan, S.2    Ensrud, K.3    Palermo, L.4    McGowan, J.A.5    Lang, T.F.6
  • 6
    • 2442515292 scopus 로고    scopus 로고
    • The use of biochemical markers in osteoporosis
    • Hammett-Stabler CA. The use of biochemical markers in osteoporosis. Clin Lab Med. 2004;24:175-97.
    • (2004) Clin Lab Med , vol.24 , pp. 175-197
    • Hammett-Stabler, C.A.1
  • 7
    • 9144233479 scopus 로고    scopus 로고
    • The effect of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
    • Muenier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, et al. The effect of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-68.
    • (2004) N Engl J Med , vol.350 , pp. 459-468
    • Muenier, P.J.1    Roux, C.2    Seeman, E.3    Ortolani, S.4    Badurski, J.E.5
  • 8
    • 21044447888 scopus 로고    scopus 로고
    • Strontium ranelate reduces risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
    • Reginster JY, Seeman E, Vernejoul MC, Adami S, Compston J, et al. Strontium ranelate reduces risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90(5):2816-22.
    • (2005) J Clin Endocrinol Metab , vol.90 , Issue.5 , pp. 2816-2822
    • Reginster, J.Y.1    Seeman, E.2    Vernejoul, M.C.3    Adami, S.4    Compston, J.5
  • 9
    • 0034520866 scopus 로고    scopus 로고
    • Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs
    • Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int. 2000;11:Suppl 6:S66-76.
    • (2000) Osteoporos Int , vol.11 , Issue.6 SUPPL.
    • Delmas, P.D.1
  • 10
    • 15344339645 scopus 로고    scopus 로고
    • Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in paget's disease of bone
    • Alexandersen P, Peris P, Guañabens N, Byrjalsen I, Alvarez L, Solberg H, et al. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in paget's disease of bone. J Bone Miner Res. 2005;20(4):588-95.
    • (2005) J Bone Miner Res , vol.20 , Issue.4 , pp. 588-595
    • Alexandersen, P.1    Peris, P.2    Guañabens, N.3    Byrjalsen, I.4    Alvarez, L.5    Solberg, H.6
  • 11
    • 34147128320 scopus 로고    scopus 로고
    • Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
    • Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007;92:1296-304
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 1296-1304
    • Delmas, P.D.1    Vrijens, B.2    Eastell, R.3    Roux, C.4    Pols, H.A.5    Ringe, J.D.6
  • 12
    • 41949116041 scopus 로고    scopus 로고
    • Role of biochemical markers of bone turnover as a prognostic indicator of successful osteoporosis therapy
    • Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O. Role of biochemical markers of bone turnover as a prognostic indicator of successful osteoporosis therapy. Bone. 2008;42(5):832-6.
    • (2008) Bone , vol.42 , Issue.5 , pp. 832-836
    • Reginster, J.Y.1    Collette, J.2    Neuprez, A.3    Zegels, B.4    Deroisy, R.5    Bruyere, O.6
  • 13
    • 23944452399 scopus 로고    scopus 로고
    • Therapeutic potential of parathyroid hormone
    • Cosman F, Linasay R. Therapeutic potential of parathyroid hormone. Curr Osteoporos Rep. 2004;2(1):5-11.
    • (2004) Curr Osteoporos Rep , vol.2 , Issue.1 , pp. 5-11
    • Cosman, F.1    Linasay, R.2
  • 14
    • 33947504500 scopus 로고    scopus 로고
    • Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial
    • Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007;146(5):326-39.
    • (2007) Ann Intern Med , vol.146 , Issue.5 , pp. 326-339
    • Greenspan, S.L.1    Bone, H.G.2    Ettinger, M.P.3    Hanley, D.A.4    Lindsay, R.5    Zanchetta, J.R.6
  • 15
    • 40849124001 scopus 로고    scopus 로고
    • Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
    • Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93(3):852-60.
    • (2008) J Clin Endocrinol Metab , vol.93 , Issue.3 , pp. 852-860
    • Boonen, S.1    Marin, F.2    Obermayer-Pietsch, B.3    Simões, M.E.4    Barker, C.5    Glass, E.V.6
  • 16
    • 26044477835 scopus 로고    scopus 로고
    • Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size
    • Burr DB. Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos. 2005;3(1):19-24.
    • (2005) Curr Osteoporos , vol.3 , Issue.1 , pp. 19-24
    • Burr, D.B.1
  • 17
    • 23744447531 scopus 로고    scopus 로고
    • Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
    • McClung MR, Sam Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165(15):1762-8.
    • (2005) Arch Intern Med , vol.165 , Issue.15 , pp. 1762-1768
    • McClung, M.R.1    Sam Martin, J.2    Miller, P.D.3    Civitelli, R.4    Bandeira, F.5    Omizo, M.6
  • 18
    • 45149119618 scopus 로고    scopus 로고
    • Randomized trial of once-weekly PTH (1-84) on bone mineral density and remodeling
    • [Epub 2008 Mar 18]
    • Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt D, Rosen E, et al. Randomized trial of once-weekly PTH (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab. 2008;93(6):2166-72. [Epub 2008 Mar 18]
    • (2008) J Clin Endocrinol Metab , vol.93 , Issue.6 , pp. 2166-2172
    • Black, D.M.1    Bouxsein, M.L.2    Palermo, L.3    McGowan, J.A.4    Newitt, D.5    Rosen, E.6
  • 19
    • 23044456161 scopus 로고    scopus 로고
    • Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy
    • Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab. 2005;90:3970-7.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 3970-3977
    • Dobnig, H.1    Sipos, A.2    Jiang, Y.3    Fahrleitner-Pammer, A.4    Ste-Marie, L.G.5    Gallagher, J.C.6
  • 20
    • 33646045900 scopus 로고    scopus 로고
    • Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in post menopausal women with osteoporosis
    • Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in post menopausal women with osteoporosis. J Clin Endocrinol Metab. 2006;91(4):1370-5.
    • (2006) J Clin Endocrinol Metab , vol.91 , Issue.4 , pp. 1370-1375
    • Bauer, D.C.1    Garnero, P.2    Bilezikian, J.P.3    Greenspan, S.L.4    Ensrud, K.E.5    Rosen, C.J.6
  • 21
    • 0345305666 scopus 로고    scopus 로고
    • Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis
    • Hodsman D, Hanley M, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, et al. Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003;88(11):5212-20.
    • (2003) J Clin Endocrinol Metab , vol.88 , Issue.11 , pp. 5212-5220
    • Hodsman, D.1    Hanley, M.2    Ettinger, M.P.3    Bolognese, M.A.4    Fox, J.5    Metcalfe, A.J.6
  • 23
    • 36049045483 scopus 로고    scopus 로고
    • Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: Results from the EUROFORS study
    • Graeff C, Timm W, Nickelsen NT, Farrerons J, Marín F, Barker C, et al. Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res. 2007;22:1426-33.
    • (2007) J Bone Miner Res , vol.22 , pp. 1426-1433
    • Graeff, C.1    Timm, W.2    Nickelsen, N.T.3    Farrerons, J.4    Marín, F.5    Barker, C.6
  • 24
    • 33845890326 scopus 로고    scopus 로고
    • Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-Term Extension (FLEX): A randomized trial
    • Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandft SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-Term Extension (FLEX): A randomized trial. JAMA. 2006;296(24):2927-38.
    • (2006) JAMA , vol.296 , Issue.24 , pp. 2927-2938
    • Black, D.M.1    Schwartz, A.V.2    Ensrud, K.E.3    Cauley, J.A.4    Levis, S.5    Quandft, S.A.6
  • 25
    • 84857786571 scopus 로고    scopus 로고
    • Relationship between 3-month changes in biochemical markers of bone remodeling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years
    • Oct 8. [Epub ahead of print]
    • Bruyère O, Collette J, Rizzoli R, et al. Relationship between 3-month changes in biochemical markers of bone remodeling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int. 2009 Oct 8. [Epub ahead of print]
    • (2009) Osteoporos Int
    • Bruyère, O.1    Collette, J.2    Rizzoli, R.3
  • 26
    • 68949100644 scopus 로고    scopus 로고
    • Comparative effects of tereparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis
    • Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of tereparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 2009;24(08):1358-68.
    • (2009) J Bone Miner Res , vol.24 , Issue.8 , pp. 1358-1368
    • Recker, R.R.1    Marin, F.2    Ish-Shalom, S.3
  • 27
    • 0036922499 scopus 로고    scopus 로고
    • Prevention of early postmenopausal bone loss by strontium ranelate: The randomized two-year, double-masked, dose ranging, placebo-controlled PREVOS study
    • Reginster JY, Deroisy R, Dougados M, et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized two-year, double-masked, dose ranging, placebo-controlled PREVOS study. Osteoporos Int. 2002;13:925-31.
    • (2002) Osteoporos Int , vol.13 , pp. 925-931
    • Reginster, J.Y.1    Deroisy, R.2    Dougados, M.3
  • 28
    • 18344379873 scopus 로고    scopus 로고
    • Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis - a two-year randomized placebo controlled trial
    • Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a two-year randomized placebo controlled trial. J Clin Endocrinal Metab. 2002;87:2060-6.
    • (2002) J Clin Endocrinal Metab , vol.87 , pp. 2060-2066
    • Meunier, P.J.1    Slosman, D.O.2    Delmas, P.D.3
  • 29
    • 68949100645 scopus 로고    scopus 로고
    • Could strontium ranelate have a synergistic role in the treatment of osteoporosis?
    • Blake GM, Compston JE, Fogelman I. Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J Bone Miner Res. 2009;24(08):1354-7.
    • (2009) J Bone Miner Res , vol.24 , Issue.8 , pp. 1354-1357
    • Blake, G.M.1    Compston, J.E.2    Fogelman, I.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.